- $473.31m
- $549.31m
- $170.44m
Regenxbio falls after FDA rejects rare disease therapy
Brief: REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
NASDAQ RESUMED AT 04:40 PM
US FDA declines to approve Regenxbio's rare disease drug (updated)
US FDA declines to approve Regenxbio's rare disease drug
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM
U.S. STOCKS ON THE MOVE-Applied Materials, Sherwin-Williams, Caterpillar
U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker International
US FDA places clinical hold on Regenxbio's rare disease program (updated)
Regenxbio tumbles as FDA halts rare‑disease gene therapy trials after tumor case
US FDA places clinical hold on Regenxbio's gene therapy trials
Brief: Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program
Brief: Regenxbio Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Regenxbio Q3 revenue rises 23%
Brief: Regenxbio Q3 License & Royalty Revenue USD 23.605 Million
Brief: REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program
Brief: Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for WET AMD
Brief: Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii